Literature DB >> 22084366

Predicting survival after curative colectomy for cancer: individualizing colon cancer staging.

Martin R Weiser1, Mithat Gönen, Joanne F Chou, Michael W Kattan, Deborah Schrag.   

Abstract

PURPOSE: Cancer staging determines extent of disease, facilitating prognostication and treatment decision making. The American Joint Committee on Cancer (AJCC) TNM classification system is the most commonly used staging algorithm for colon cancer, categorizing patients on the basis of only these three variables (tumor, node, and metastasis). The purpose of this study was to extend the seventh edition of the AJCC staging system for colon cancer to incorporate additional information available from tumor registries, thereby improving prognostic accuracy.
METHODS: Records from 128,853 patients with primary colon cancer reported to the Surveillance, Epidemiology and End Results Program from 1994 to 2005 were used to construct and validate three survival models for patients with primary curative-intent surgery. Independent training/test data sets were used to develop and test alternative models. The seventh edition TNM staging system was compared with models supplementing TNM staging with additional demographic and tumor variables available from the registry by calculating a concordance index, performing calibration, and identifying the area under receiver operating characteristic (ROC) curves.
RESULTS: Inclusion of additional registry covariates improved prognostic estimates. The concordance index rose from 0.60 (95% CI, 0.59 to 0.61) for the AJCC model, with T- and N-stage variables, to 0.68 (95% CI, 0.67 to 0.68) for the model including tumor grade, number of collected metastatic lymph nodes, age, and sex. ROC curves for the extended model had higher sensitivity, at all values of specificity, than the TNM system; calibration curves indicated no deviation from the reference line.
CONCLUSION: Prognostic models incorporating readily available data elements outperform the current AJCC system. These models can assist in personalizing treatment and follow-up for patients with colon cancer.

Entities:  

Mesh:

Year:  2011        PMID: 22084366      PMCID: PMC3664036          DOI: 10.1200/JCO.2011.36.5080

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  21 in total

1.  Time-dependent ROC curves for censored survival data and a diagnostic marker.

Authors:  P J Heagerty; T Lumley; M S Pepe
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

2.  Whither TNM?

Authors:  Mithat Gönen; Martin R Weiser
Journal:  Semin Oncol       Date:  2010-02       Impact factor: 4.929

3.  Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection.

Authors:  Natalie E Joseph; Elin R Sigurdson; Alexandra L Hanlon; Hao Wang; Robert J Mayer; John S MacDonald; Paul J Catalano; Daniel G Haller
Journal:  Ann Surg Oncol       Date:  2003-04       Impact factor: 5.344

4.  Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology.

Authors:  C E Desch; A B Benson; T J Smith; P J Flynn; C Krause; C L Loprinzi; B D Minsky; N J Petrelli; D G Pfister; M R Somerfield
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

Review 5.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.

Authors:  Al B Benson; Deborah Schrag; Mark R Somerfield; Alfred M Cohen; Alvaro T Figueredo; Patrick J Flynn; Monika K Krzyzanowska; Jean Maroun; Pamela McAllister; Eric Van Cutsem; Melissa Brouwers; Manya Charette; Daniel G Haller
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

6.  A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results.

Authors:  Hideshige Koh; Michael W Kattan; Peter T Scardino; Kazuho Suyama; Norio Maru; Kevin Slawin; Thomas M Wheeler; Makoto Ohori
Journal:  J Urol       Date:  2003-10       Impact factor: 7.450

7.  Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.

Authors:  T E Le Voyer; E R Sigurdson; A L Hanlon; R J Mayer; J S Macdonald; P J Catalano; D G Haller
Journal:  J Clin Oncol       Date:  2003-08-01       Impact factor: 44.544

8.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Authors:  Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging.

Authors:  Jessica B O'Connell; Melinda A Maggard; Clifford Y Ko
Journal:  J Natl Cancer Inst       Date:  2004-10-06       Impact factor: 13.506

10.  Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.

Authors:  James A Eastham; William K Kelly; Gary D Grossfeld; Eric J Small
Journal:  Urology       Date:  2003-12-29       Impact factor: 2.649

View more
  65 in total

Review 1.  Nomograms in oncology: more than meets the eye.

Authors:  Vinod P Balachandran; Mithat Gonen; J Joshua Smith; Ronald P DeMatteo
Journal:  Lancet Oncol       Date:  2015-04       Impact factor: 41.316

2.  Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?

Authors:  H Ishida; K Kumamoto; K Ishibashi; S Hatano; T Matsuzawa; N Okada; Y Kumagai; H Baba; N Haga
Journal:  Tech Coloproctol       Date:  2013-02-07       Impact factor: 3.781

3.  Dose-response Effects of Aerobic Exercise Among Colon Cancer Survivors: A Randomized Phase II Trial.

Authors:  Justin C Brown; Andrea B Troxel; Bonnie Ky; Nevena Damjanov; Babette S Zemel; Michael R Rickels; Andrew D Rhim; Anil K Rustgi; Kerry S Courneya; Kathryn H Schmitz
Journal:  Clin Colorectal Cancer       Date:  2017-06-17       Impact factor: 4.481

4.  Predicting Individualized Postoperative Survival for Stage II/III Colon Cancer Using a Mobile Application Derived from the National Cancer Data Base.

Authors:  Emmanuel Gabriel; Kristopher Attwood; Pragatheeshwar Thirunavukarasu; Eisar Al-Sukhni; Patrick Boland; Steven Nurkin
Journal:  J Am Coll Surg       Date:  2015-12-23       Impact factor: 6.113

5.  Peripheral Neutrophil to Lymphocyte Ratio Improves Prognostication in Colon Cancer.

Authors:  Shahrooz Rashtak; Xiaoyang Ruan; Brooke R Druliner; Hongfang Liu; Terry Therneau; Mohamad Mouchli; Lisa A Boardman
Journal:  Clin Colorectal Cancer       Date:  2017-01-25       Impact factor: 4.481

6.  A prognostic nomogram for prediction of recurrence in desmoid fibromatosis.

Authors:  Aimeé M Crago; Brian Denton; Sébastien Salas; Armelle Dufresne; James J Mezhir; Meera Hameed; Mithat Gonen; Samuel Singer; Murray F Brennan
Journal:  Ann Surg       Date:  2013-08       Impact factor: 12.969

Review 7.  What is the optimal means of staging colon cancer?

Authors:  Elizabeth A Arena; Anton J Bilchik
Journal:  Adv Surg       Date:  2013

8.  The complexity of the count: considerations regarding lymph node evaluation in colorectal carcinoma.

Authors:  Laura J Denham; Justin C Kerstetter; Paul C Herrmann
Journal:  J Gastrointest Oncol       Date:  2012-12

9.  AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment?

Authors:  Danielle M Hari; Anna M Leung; Ji-Hey Lee; Myung-Shin Sim; Brooke Vuong; Connie G Chiu; Anton J Bilchik
Journal:  J Am Coll Surg       Date:  2013-06-12       Impact factor: 6.113

10.  Real-world study of a novel prognostic scoring system: for a more precise prognostication and better clinical treatment guidance in stages II and III colon cancer.

Authors:  Qi Liu; Yanlei Ma; Dakui Luo; Sanjun Cai; Qingguo Li; Xinxiang Li
Journal:  Int J Colorectal Dis       Date:  2018-05-16       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.